Not provided
Not provided
Not provided
Not provided
Not provided
Too challenging to recruit appropriate participants at an acceptable speed.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The present study will compare lixisenatide and liraglutide in a population of subjects with T2DM not optimally controlled on OADs and / or insulin, which is the target population for these medications.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Liraglutide | Experimental | The highest injected once daily dose will be 1.8 mg s.c. for liraglutide. |
|
| Lixisenatide | Experimental | The highest injected once daily dose will be 20µg s.c. for lixisenatide. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Liraglutide | Drug |
| ||
| Lixisenatide |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline (week -1) in the number of reflux episodes | 24 hours after 10 weeks of treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline (week -1) in the time of pH < 4.0 in the lower third of the oesophagus | After 10 weeks of treatment |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Juris Meier, MD | St. Josef Hospital Bochum | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| St. Josef-Hospital, Universitätsklinik | Bochum | 44791 | Germany | |||
| Profil Institut für Stoffwechselforschung GmbH |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 32647054 | Derived | Quast DR, Schenker N, Menge BA, Nauck MA, Kapitza C, Meier JJ. Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes. Diabetes Care. 2020 Sep;43(9):2137-2145. doi: 10.2337/dc20-0720. Epub 2020 Jul 9. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| ID | Term |
|---|---|
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000069450 | Liraglutide |
| C479460 | lixisenatide |
| ID | Term |
|---|---|
| D052216 | Glucagon-Like Peptide 1 |
| D004763 | Glucagon-Like Peptides |
| D052336 | Proglucagon |
| D005768 | Gastrointestinal Hormones |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Neuss |
| 41460 |
| Germany |
| D006728 |
| Hormones |
| D006730 | Hormones, Hormone Substitutes, and Hormone Antagonists |